Get the Stockscreener App
1.58
6.51%
-0.11
After Hours:
1.58
Esperion Therapeutics Inc stock is traded at $1.58, with a volume of 6.18M.
It is down -6.51% in the last 24 hours and down -15.05% over the past month.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
See More
Previous Close:
$1.69
Open:
$1.67
24h Volume:
6.18M
Relative Volume:
1.16
Market Cap:
$299.35M
Revenue:
$116.33M
Net Income/Loss:
$-209.25M
P/E Ratio:
-0.7453
EPS:
-2.12
Net Cash Flow:
$-135.49M
1W Performance:
+0.00%
1M Performance:
-15.05%
6M Performance:
-8.67%
1Y Performance:
-27.85%
1-Day Range:
$1.56
$1.71
1-Week Range:
$1.56
$1.8089
52-Week Range:
$1.56
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
1.58 | 299.35M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
171.80 | 76.93B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.04 | 47.47B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.37 | 46.89B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.67 | 16.81B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.25 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Q3 Earnings Forecast for ESPR Issued By HC Wainwright - Defense World
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y - MSN
Esperion Therapeutics, Inc. SEC 10-K Report - TradingView
Brokers Set Expectations for ESPR Q1 Earnings - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts - Defense World
Esperion stock target holds at $4 on JMP’s optimistic outlook By Investing.com - Investing.com South Africa
Esperion stock target holds at $4 on JMP’s optimistic outlook - Investing.com
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4 - MSN
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright - Defense World
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart
Esperion stock hits 52-week low at $1.58 amid challenges By Investing.com - Investing.com Australia
Esperion Therapeutics Reports Strong Revenue Growth in 2024 - TipRanks
Esperion Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Esperion Therapeutics stock surges over 9% on strong Q4 results - Investing.com
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Esperion Therapeutics Q4 Loss Narrows - Nasdaq
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Esperion Therapeutics stock surges over 9% on strong Q4 results By Investing.com - Investing.com Canada
ESPERION THERAPEUTICS Earnings Results: $ESPR Reports Quarterly Earnings - Nasdaq
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire Inc.
Csl Ltd Says CSL Seqirus & Esperion Sign Licensing Agreement -March 03, 2025 at 08:01 pm EST - Marketscreener.com
Esperion stock hits 52-week low at $1.58 amid challenges - Investing.com
Esperion Therapeutics Q4 2024 Earnings Preview - MSN
Esperion inks deal for cholesterol drugs in Australia, NZ By Investing.com - Investing.com Canada
Esperion inks deal for cholesterol drugs in Australia, NZ - Investing.com
Esperion Therapeutics (ESPR) Partners with CSL Seqirus to Commercialize NEXLETOL and NEXLIZET in Australia - StreetInsider.com
Esperion Partners with CSL Seqirus to Commercialize - GlobeNewswire
Can Esperion's Australian Drug Partnership Unlock a 1.2M Patient Market? - StockTitan
ESPERION THERAPEUTICS Earnings Preview: Recent $ESPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Esperion Therapeutics (ESPR) Projected to Post Earnings on Tuesday - Defense World
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now? - Insider Monkey
Esperion Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Sigma Planning Corp Has $419,000 Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat
Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics CFO sells shares for $20 By Investing.com - Investing.com Nigeria
Esperion Therapeutics executive sells shares worth $446 - Investing.com India
Esperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Esperion Therapeutics CFO sells shares for $20 - Investing.com India
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest - MarketBeat
Zacks Research Has Pessimistic Outlook of ESPR Q3 Earnings - MarketBeat
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - The Manila Times
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):